Sat, Dec 20, 2014, 4:46 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Biodel Inc. (BIOD) Message Board

  • thendy_patty thendy_patty Sep 4, 2013 10:45 AM Flag

    Why phase2 will be successful, the answer is there in 2010 trial results.

    As per Dr. Rodbard, this study demonstrated the non-inferiority of the new more-rapid-acting injectable human insulin versus regular human insulin and the favorable impact of the faster-acting insulin on hypoglycemia and weight gain, two key side effects of currently marketed insulins which can be difficult to manage. These findings are encouraging and suggest that we can achieve proper glycemic control with reduced hypoglycemia and weight gain through the use of a more-rapid-acting form of human insulin''. Dr. Rodbard is a practicing endocrinologist based in Rockville, Maryland, a Master of the American College of Endocrinology (MACE), a Fellow of the American College of Physicians (FACP) and past president of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.39+0.03(+2.21%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.